Date: 2016-01-11
Type of information: Nomination
Compound:
Company: Celgene (USA - NJ)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 11, 2016, Celgene announced organizational changes that will position the Company for continued long-term growth. Effective March 1, 2016 Bob Hugin will serve as Executive Chairman, he will continue to lead the Board of Directors and manage the strategic direction of the company. Mark Alles will be promoted to Chief Executive Officer (CEO) and Jacqualyn Fouse , PhD, will be promoted to President and Chief Operating Officer (COO). Scott Smith , President Immunology & Inflammation, will assume an expanded leadership role
Mark Alles is a three-decade industry veteran and has been with Celgene since 2004, most recently serving as President & COO. As President & COO, Mark integrated Celgene's corporate operational functions in support of its global commercial franchises. Before serving as President & COO, Mark built and led Celgene's Hematology & Oncology franchise, including leading the global launches of Revlimid® and Pomalyst® and the acquisitions and integrations of Pharmion (Vidaza®) and Abraxis BioSciences (Abraxane®). Under Mark's leadership, the Hematology & Oncology franchise consistently produced extraordinary results, laying the foundation for long-term industry leading growth.
Jackie Fouse will be promoted to President & COO. Jackie joined Celgene in 2010 as Chief Financial Officer and has excelled as both the leader of Celgene's Finance department and in her current role as President of Celgene's Hematology & Oncology franchise. As President & COO, Jackie will focus on further enhancing Celgene's commitment to operational excellence, driving exceptional performance across Celgene's franchises and functions. Reporting to Jackie in this role will be Celgene's corporate operational functions as well as the Hematology & Oncology and I&I franchises.
Scott Smith , President of Celgene's I&I franchise, will be appointed to chair Celgene's Global Management Committee. As Chair of Celgene's Global Management Committee, Scott will be responsible for the effective coordination of Celgene's operational and strategic imperatives. Scott joined Celgene in 2008 and will continue to be responsible for building and leading Celgene's I&I franchise.
Financial terms:
Latest news:
Is general: Yes
